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          Cytochrome P450 3A4 (CYP3A4) is a phase 1 metabolism 
enzyme which is responsible for the metabolism of about 30-
40% drug in the market.  This CYP3A4 is the most abundant 
CYP450 expressed in human body and also the one who is 
responsible for the biotransformation of most drugs. The 
competitive inhibition of curcumin (a yellow bioactive pigment 
discovered in Curcuma sp.) towards human CYP3A4 indicates 
that curcumin can be a substrate for the enzyme. In this study, 
in silico approaches employing molecular docking and interaction 
fingerprinting were used to predict the binding mode and the site 
of metabolism (SOM) of curcumin. Together with the SOMs 
retrieved previously and the list of possible reactions catalyzed 
by CYP3A4, the docking and fingerprinting results indicate that 
the most probable metabolite of curcumin metabolism by human 
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Cytochrome P450 3A4 (CYP3A4) is a 
part of the large protein family responsible in 
the phase 1 metabolism Cytochrome P450 
(CYP450). This CYP3A4 is the most abundant 
CYP450 expressed in human body and also the 
one who is responsible for the 
biotransformation of most drugs available in 
the market (Rendic, 2002). The 
biotransformation catalyzed by this enzyme, 
including oxidation, hydroxylation, and 
heteroalkyl removal, depends on the binding 
mode and the reactivity of specific moiety of 
the drug (Rendic, 2002; Appiah-Opong et al., 
2008). This enzyme plays an important role in 
the drug-medicinal plants interactions (Appiah-
Opong et al., 2008; Appiah-Opong et al., 2008). 
This indicates the probabilities of some 
bioactive compounds in the plants that serve as 
inhibitor or substrate for CYP3A4. 
Interestingly, the studies on CYP3A4 
performed by Appiah-Opong et al. (2008) 
employed human CYP3A4 instead of animal 
models since the species differences could be 
detrimental for the conclusion drawing of the 
efficacy and safety potency of drug candidates 
(Komura and Iwaki, 2011).  
The metabolism of curcumin (the yellow 
bioactive pigment discovered in Curcuma sp. 
(Kunwar et al., 2008; Basnet and Skalko-Basnet, 
2011)) by CYP3A4 is of considerable of 
interest (Asai and Miyazawa, 2000; Ireson et al., 
2001; Hoehle et al., 2006; Anand et al., 2007; 
Tamvakopoulos et al., 2007; Appiah-Opong et 
al., 2008). However, the fate of curcumin inside 
human body remains vague (Appiah-Opong et 
al., 2007; Appiah-Opong et al., 2008). Most 
clues about the fate of curcumin were collected 
from in vitro and in vivo studies using animal 
models (Asai and Miyazawa, 2000; Ireson et al., 
2001; Hoehle et al., 2006; Anand et al., 2007; 
Tamvakopoulos et al., 2007). Fortunately, there 
were clear evidences shown that curcumin 
inhibits human CYP450 enzymes (i.e. CYP1A2, 
CYP2B6, and CYP3A4) in a competitive 
manner (Appiah-Opong et al., 2007; Appiah-
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Opong et al., 2008). Notably, amongst other 
tested human CYP450 enzymes, curcumin 
shows the highest inhibitory activity towards 
human CYP3A4 (Appiah-Opong et al., 2007). 
Hence, it is certain that curcumin binds to the 
active site of human CYP3A4 and probably 
acts as a substrate for the enzyme. 
Several studies have shown that in silico 
methods can predict the potential susceptibility 
of a substrate towards certain CYP450 
enzymes. An integrated in silico study even 
capable to predict the possible metabolites 
produced by CYP450 (de Graaf et al., 2005, 
2006). Especially for CYP450 2D6 (CYP2D6), 
de Graaf et al. (2006) have constructed in silico 
structure-based virtual screening protocols to 
predict the site of metabolism (SOM) of 
substrates accurately and based on the SOM 
one could subsequently suggest the possible 
metabolites. On the other hand, computer-
aided quantitative structure-activity relationship 
(QSAR) studies on curcumin and its analogs as 
inhibitors for several human CYP450, including 
CYP3A4 have been performed (Appiah-Opong 
et al., 2008).  The QSAR studies suggested a 
statistically significant QSAR model on 
curcumin analogs as CYP3A4 inhibitor 
(Appiah-Opong et al., 2008). However, though 
the QSAR approaches successfully presented 
the prominent role of in silico methods in the 
studies of curcumin-CYP3A4 interaction 
(Appiah-Opong et al., 2008), the binding pose 
of curcumin in the CYP3A4 active pocket 
remains unclear. Notably, the broad selectivity 
of CYP3A4 (Rendic, 2002) and the inhibitory 
activity of curcumin towards this enzyme 
(Appiah-Opong et al., 2007; Appiah-Opong et 
al., 2008) make this enzyme worth to consider 
as the enzyme responsible for curcumin 
biotransformation. The availability of the 
crystal structure of human CYP3A4 
(Sevrioukova and Poulos, 2012) offers the 
opportunities to predict the interaction between 
curcumin and CYP3A4 using in silico structure-
based approaches. These approaches have the 
advantage of giving the insight of protein-
ligand interaction (de Graaf et al., 2005). The 
structure-based approaches can hopefully show 
which moiety of curcumin that interacts with 
the CYP3A4 heme Fe-atom. Therefore,           
these approaches can be used to define the 
potential SOM of curcumin metabolized 
CYP3A4. 
The research presented in this paper was 
aimed to elucidate the binding mode of 
curcumin in the CYP3A4 active site using valid 
in silico structure-based protocols and 
subsequently predict the SOM and the 
probable metabolite of curcumin by inspecting 
visually the curcumin-CYP3A4 interaction. 
Initially, the in silico structure-based protocols 
involving molecular docking method were 
internally validated by redocking the co-crystal 
ligand (Marcou and Rognan, 2007; Sevrioukova 
and Poulos, 2012). The valid protocols were 
subsequently employed to elucidate the binding 
mode of curcumin in the CYP3A4 active site. 
The visual inspection of the binding mode of 
curcumin identified the potential SOM of 
curcumin and lead to the prediction of the first 





The crystal structure of human CYP3A4 
bound to bromoergocryptine (BEC) obtained 
from protein data bank (PDB) with PDB code 
of 3UA1 was used as the reference structure 
(Sevrioukova and Poulos, 2012). The digital 
form of curcumin structure in the β-diketo 
tautomer was obtained from Chemical Entities 
of Biological Interest (ChEBI) database 
(https://www.ebi.ac.uk/chebi/init.do) with 
ChEBI-ID of CHEBI:3962 (European 
Bioinformatics Institute, 2012). The 
configurations for the docking simulations were 
provided by Yuniarti et al. (2011). All 
computational simulations were performed on 
a Hewlett-PackardTM HP 430 workstation with 
Intel® CoreTM i3 as the processor and 2 GB of 
RAM and Linux 2.6.32-30-generic (Ubuntu 
10.04 Lucid) as the operating system. 
Computational medicinal chemistry 
applications employed in this research were 
SPORES (ten Brink and Exner, 2009), 
PLANTS1.2   (Korb et al., 2009),  Open   Babel 
2.2.3 (O’Boyle et al., 2011), PyPLIF 0.1.1 
(Radifar, 2012), MarvinSketch 5.10.0 
(ChemAxon, 2009) and PyMOL 1.2r1 (Lill and 
Danielson, 2011). Statistical analysis was 
performed by using R 2.14.0 (R Development 
Core Team, 2008).     
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Computational methods 
Molecular  docking protocols construc-
tion  and internal validation 
The virtual target file (protein.mol2) was 
prepared by employing the rule-based 
recognition of protonation, tautomeric, and 
stereoisomeric states of SPORES (ten Brink 
and Exner, 2009) subjected to the reference 
structure. The binding pocket of the human 
CYP3A4 was defined by the coordinates of the 
co-crystalized BEC in the 3UA1 structure 
(Sevrioukova and Poulos, 2012) and a radius of 
14.401Å, which is the maximum distance from 
the center defined by a 5Å radius (de Graaf et 
al., 2011) around BEC. Based on this binding 
pocket definition, the default configuration 
(Tabel I) was prepared according to the default 
configuration previously described by Yuniarti 
et al. (2011). In the visual inspection of the 
3UA1 structure using PyMOL 1.2 (Lill and 
Danielson, 2011), several hydrogen bond 
interactions of BEC to the residues in the 
binding pocket, including the hydrogen bond 
interactions to SER119, ARG212, and 
THR224, were observed (Sevrioukova and 
Poulos, 2012). The hydrogen bond interaction 
of BEC to SER119 amongst other was 
observed as the nearest one (6.1Å) from the 
CYP3A4 heme Fe-atom (Sevrioukova and 
Poulos, 2012). Yuniarti et al. (2011) suggested a 
hydrogen bond anchor in order to increase the 
virtual screening quality. Therefore, beside the 
default molecular docking configuration, a 
modified configuration with 100 times 
hydrogen bonding constraint to SER119 was 
prepared (Table II). 
The internal validations were performed 
for each configuration by redocking the co-
crystalized ligand BEC into the virtual target 
using the docking software PLANTS1.2 (Korb 
et al., 2009) and subsequently compared the 
docking pose to the original crystal structure 
pose (Marcou and Rognan, 2007; Sevrioukova 
and Poulos, 2012). The objective function used 
in the internal validation was the root mean 
square distance (RMSD) value between the 
heavy atoms of the docked pose and the crystal 
structure pose. A docking protocol is 
acceptable if the RMSD value is less than 2.0Å 
(Marcou and Rognan, 2007). The RMSD values 
were calculated using rms_cur module in 
PyMOL 1.2r1. 
Ligand preparation steps 
The optimized state of the lowest energy 
conformer of the co-crystalized ligand BEC 
was used as the input ligand. This optimized 
state was prepared by employing Open Babel 
2.2.3 (O’Boyle et al., 2011). The hydrogen 
atoms in pH 7.4 was added to the input ligand 
by module babel –p 7.4 and followed by 
module obconformer to perform conformer 
search using Monte Carlo simulations with 
maximum 250 conformers and followed by 
energy optimization using steepest descent 
method with maximum 100 steps. This ligand 
preparation step was performed 10 times to 
have 10 different starting points. Each prepared 
ligand were subsequently docked independently 
to the virtual target by employing PLANTS1.2 
(Korb et al., 2009). For each independent 
docking simulation, the best docked pose was 
automatically suggested by the software by 
selecting a pose with the lowest ChemPLP 
score. 
 
Rescoring using protein-ligand 
interaction fingerprints calculated by 
PyPLIF  
The docked poses resulted from the 
previous subsection were subjected to PyPLIF 
(Radifar, 2012) in order to calculate the protein-
ligand interaction fingerprint (PLIF) bitstrings. 
The bitstrings were subsequently compared to 
the PLIF bitstrings of protein-ligand 
interactions of the crystal structure pose of 
ligand (BEC) to the defined binding pocket of 
the crystal structure of protein (3UA1) using 
Tanimoto similarity (Tc-PLIF) coefficient 
(Radifar, 2012). By using PyPLIF, the pose with 
the highest Tc-PLIF value was assigned as the 
selected pose instead of the pose with the 
lowest ChemPLP score. 
 
Considering stereoisomer constraint in 
the ligand preparation step 
The module obconformer in OpenBabel 
2.2.3 could not provide the stereoisomer 
constraint (O’Boyle et al., 2011). Therefore, 
beside the ligand preparation steps without 
stereoisomer constraint described in the 
previous sub section, other ligand preparation 
steps with the stereoisomer constraint were 
performed. Since the automatic option to 
constraint the stereoisomer was not available in 
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the module obconformer of OpenBabel 2.2.3 
(O’Boyle et al., 2011), the stereoisomer of each 
prepared ligand was manually checked and the 
ligand preparation step was redone if the 
prepared ligand was not in the same 
stereoisomer state with the co-crystalized ligand 
BEC (Sevrioukova and Poulos, 2012). This 
ligand preparation step was performed several 
times until 10 different starting point ligands 
with the same stereoisomer state with the co-
crystalized ligand BEC were available. Each 
prepared ligand were subsequently docked 
independently to the virtual target by 
employing PLANTS1.2 (Korb et al., 2009). The 
subsequent docking rescoring using PyPLIF 
0.1.1 (Radifar, 2012) were also performed to 
the docked poses. 
 
Docking simulation of curcumin  
Curcumin in the β-diketo tautomer 
obtained from the ChEBI database was 
prepared using the previously described ligand 
preparation procedure. On the other hand, 
curcumin in the keto-enol tautomer was built in 
the two dimension (2D) form using 
MarvinSketch and using the module Major 
Microspecies the major microspecies in pH 7.4 
was checked and subsequently the 10 different 
conformers were built using the default setting 
of the module Conformers. The 10 different 
conformers were then exported as a .mol2 file.  
For each tautomer, 10 prepared ligands 
were provided independently as the starting 
points for the docking simulations. The best 
pose of curcumin in the binding pocket of 
human CYP3A4 from each tautomer was 
selected using the best and validated in silico 
screening protocol described in the previous 
subsections. This pose was subsequently 
inspected visually to study the SOM of 
curcumin by human CYP3A4. The SOM              
was the ligand atoms within 6.0 Å from          
the CYP3A4 heme Fe-atom (de Graaf et al., 
2006). By identification of the SOM,                    
the predicted metabolites can be subse-         
quently suggested (de Graaf et al., 2005; 
Tamvakopoulos et al., 2007). 
 
RESULTS AND DISCUSSION 
This research was aimed to construct a 
valid in silico tool to study the human CYP3A4 
enzyme-ligand interactions. In the context of 
an enzyme as catalytic receptor, the ligand can 
be a substrate or an inhibitor (de Graaf et al., 
2005). The validated tool was subsequently 
employed to examine the interactions of 
curcumin to human CYP3A4 in the atomic 
level and identify its SOM (de Graaf et al., 2005, 
2006, 2011). 
 
Constraints are important to have a 
valid and acceptable in silico tool to 
study the human CYP3A4 enzyme-
ligand interactions 
A valid crystal structure-based in silico 
tool to study how a ligand, which was 
retrospectively proven to be active in a 
receptor, interacts to the receptor should have 
at least the ability to reproduce the original 
pose of the co-crystalized ligand (Marcou and 
Rognan, 2007). The pose produced and 
selected by a valid in silico tool must have an 
RMSD value of less than 2.0Å (Marcou and 
Rognan, 2007). The RMSD values of the best 
pose selected using the lowest ChemPLP score 
from 10 independent starting points 
(Conformers 1-10) without (the default 
configuration (Table I)) and with additional 
hydrogen bond interaction constraint to 
SER119 (the modified configuration (Table II)) 
are presented in table III, while table IV 
presents the RMSD values of the best pose 
selected using the highest Tc-PLIF value. 
Different to energy-based scoring functions 
used commonly in other docking softwares 
(Tiwari et al., 2009), ChemPLP score and Tc-
PLIF are dimensionless since it is not an 
energy-based scoring functions. Instead, 
ChemPLP score is a knowledge-based empirical 
scoring functions (Korb et al., 2007, 2009), 
while Tc-PLIF is a similarity index comparing 
the PLIF bitstrings of the docked pose to the 
original co-crystalized pose (Marcou and 
Rognan, 2007). Therefore, it is not 
recommended to convert the scores to any 
affinity values. The ChemPLP score and the 
Tc-PLIF were employed to rank and assist the 
selection of the docked pose in a virtual 
screening campaign (Marcou and Rognan, 
2007; de Graaf et al., 2011).  
Based on table III and IV, none               
of these in silico protocols can be employed             
in the binding mode prediction of ligands  
when    interact    to    the    human    CYP3A4.  
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Table I. The default configuration file of the molecular docking simulations by employing 












# write single mol2 files (e.g., for RMSD calculation) 
write_multi_mol2 0 
# cluster algorithm 
cluster_structures 10 
cluster_rmsd 2.0 
# binding site definition 




Table II. The modified configuration file of the molecular docking simulations by employing 












# write single mol2 files (e.g., for RMSD calculation) 
write_multi_mol2 0 
# cluster algorithm 
cluster_structures 10 
cluster_rmsd 2.0 
# binding site definition 
bindingsite_center 22.7544 14.8129 -11.868 
bindingsite_radius 14.401 
# hydrogen bond constraint 
chemplp_protein_hb_constraint 1462 100 
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Table III. The ChemPLP scores and RMSD values of the best docked pose of BEC from 10 
independent starting points selected based on the ChemPLP score.  
 
Default Configuration Modified Configuration 
Entry  
ChemPLP RMSD (Å) ChemPLP RMSD (Å) 
Conformer  1 -133.282 3.376 -408.453 1.420 
Conformer  2 -137.117 3.476 -404.045 1.704 
Conformer  3 -124.374 1.099 -418.036 1.087 
Conformer  4 -130.179 3.550 -412.678 1.458 
Conformer  5 -130.908 3.431 -408.118 1.632 
Conformer  6 -131.322 1.416 -417.395 1.192 
Conformer  7 -130.235 3.537 -415.795 1.347 
Conformer  8 -126.439 0.903 -419.836 0.820 
Conformer  9 -125.672 1.268 -416.786 0.921 
Conformer 10 -120.002 9.159 -403.219 4.405 
 
Table IV. The Tc-PLIF and RMSD values of the best docked pose of BEC from 10 independent 
starting points selected based on the Tc-PLIF value.  
 
Default Configuration Modified Configuration 
Entry  
Tc-PLIF RMSD (Å) Tc-PLIF RMSD (Å) 
Conformer  1 0.778 1.839 0.800 1.420 
Conformer  2 0.833 1.966 0.750 1.704 
Conformer  3 0.842 1.099 0.800 1.087 
Conformer  4 0.895 1.521 0.800 1.458 
Conformer  5 0.800 1.634 0.800 1.632 
Conformer  6 0.850 1.294 0.842 1.192 
Conformer  7 0.778 3.519 0.800 1.347 
Conformer  8 0.833 0.903 0.842 0.820 
Conformer  9 0.789 1.268 0.850 0.921 
Conformer 10 0.650 4.751 0.714 5.457 
 
Table V. The ChemPLP scores and RMSD values of the best docked pose of BEC from 10 
independent stereoisomer-constrained starting points selected based on the ChemPLP score.  
 
Default Configuration Modified Configuration 
Entry  
ChemPLP RMSD (Å) ChemPLP RMSD (Å) 
Conformer 11 -127.846 3.547 -411.688 3.439 
Conformer 12 -127.120 3.377 -409.126 1.237 
Conformer 13 -127.000 3.424 -419.668 1.020 
Conformer 14 -123.060 3.535 -416.071 1.125 
Conformer 15 -132.340 3.390 -407.065 3.324 
Conformer 16 -132.649 3.405 -409.930 3.365 
Conformer 17 -125.128 0.968 -418.146 1.006 
Conformer 18 -128.565 3.420 -402.132 1.654 
Conformer 19 -128.915 3.566 -410.770 1.583 
Conformer 20 -127.234 3.603 -409.585 1.614 
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The default configuration without using 
PyPLIF (Table III) gave the worst results. 
Although the modified configuration (Table 
III) could reduce the RMSD values of 9 out of 
10 conformers until less than 2.0Å, there were 
still possibilities of the ligand to be docked in 
the incorrect pose. Similar results to the use of 
modified configuration (Table III) were shown 
by the best poses selected by using the Tc-PLIF 
value. There was always one starting point 
(conformer 10) that gave RMSD value of more 
than 2.0Å. This outlier was then inspected 
visually and it was observed that conformer 10 
had different stereoisomer compared to the 
reference co-crystalized ligand BEC and to 
other conformers. Thus, stereoisomer 
constraint in the ligand preparation step is 
highly recommended. The in silico construction 
and validation were then re-performed by 
taking into account this stereoisomer constraint 
issue.  
Another 10 conformers (Conformers 11-
20) were prepared independently and their 
stereoisomers were manually checked to make 
sure that the stereoisomer similar to the 
reference co-crystalized ligand BEC.  
The RMSD values of the best pose 
selected using the lowest ChemPLP score from 
these 10 independent stereoisomer-constrained 
starting points without (the default 
configuration (Table I)) and with additional 
hydrogen bond interaction constraint to 
SER119 (the modified configuration (Table II)) 
are presented in table V, while table VI 
presents the RMSD values of the best pose 
selected using the highest Tc-PLIF value. 
Table VI. The Tc-PLIF and RMSD values of the best docked pose of BEC from 10 independent 
stereoisomer-constrained starting points selected based on the Tc-PLIF value.  
 
Default Configuration Modified Configuration 
Entry  
Tc-PLIF RMSD (Å) Tc-PLIF RMSD (Å) 
Conformer 11 0.947 1.614 0.800 1.733 
Conformer 12 0.750 3.648 0.800 1.237 
Conformer 13 0.789 1.557 0.800 1.020 
Conformer 14 0.789 1.516 0.800 1.125 
Conformer 15 0.750 1.966 0.800 1.604 
Conformer 16 0.857 1.233 0.800 1.292 
Conformer 17 0.778 3.678 0.750 1.006 
Conformer 18 0.737 1.918 0.850 1.654 
Conformer 19 0.800 1.573 0.800 1.583 
Conformer 20 0.789 1.736 0.800 1.614 
 
Table VII. The Tc-PLIF the best docked poses of curcumin in the β-diketo and keto-enol forms in 
the binding pocket of human CYP3A4 from 10 independent runs with different starting points.   
 
Tc-PyPLIF 
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As can be seen in table V and table VI, 
the use of hydrogen bond constraint to 
SER119 and PyPLIF rescoring were important 
to be involved in a valid in silico tool to predict 
the binding mode prediction of ligands when 
interact to the human CYP3A4. The default 
configuration alone could only give 1 
acceptable RMSD value out of 10 independent 
simulations. The modified configuration or the 
use of PyPLIF could increase the quality but 
still some of the selected poses gave RMSD 
values more than 2.0Å. Only the ones that 
employing both modified configuration and 
PyPLIF rescoring gave RMSD values of less 
than 2.0Å. This indicates that interaction 
fingerprints with more attention to the ligand 
interaction  to  SER119  are  important   in  the  
binding mode prediction of a ligand in the 
binding pocket of human CYP3A4. Notably, 
this successful in silico tool construction and 
validation was stereoisomer dependent. 
Therefore, in prospective efforts employing 
this validated tool should take into account the 














Figure 2. The representative pose of curcumin (orange carbon atoms) in the binding 
pocket of human CYP3A4 (blue carbon atoms except for heme using green carbon 
atoms). Oxygen, nitrogen and Fe are colored in red, blue and brown, respectively. 
Only polar hydrogens are shown for clarity. In 2A, curcumin is depicted as balls and 
sticks and only tertiary structure, SER119 and HEME of CYP3A4 are shown. 
Hydrogen bond interaction is depicted by black dashed line. In 2B, curcumin is 
depicted as lines except for atoms within 6.0 Å from the CYP3A4 heme Fe-atom, 
which are depicted as balls and sticks. Only curcumin and HEME are presented in 2B. 
The black dashed line in 2B represents the distance between the CYP3A4 heme Fe-
atom and the most plausible SOM of curcumin. 
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Curcumin binds to human CYP3A4 
enzyme-ligand in the form of β-diketo 
tautomer 
Since curcumin is a ligand for human 
CYP3A4 (Appiah-Opong, de Esch, et al., 2008), 
we were confident to employ the previously 
validated in silico protocol, that can reproduce 
the pose of the co-crystal ligand (see previous 
subsection), to dock curcumin in and to analyze 
how curcumin binds in the binding pocket of 
CYP3A4. Curcumin can exist in two tautomers, 
i.e. β-diketo and keto-enol forms (Figure 1) 
(Istyastono et al., 2003). Based on the existence 
of these tautomers and taking into account the 
stereoisomer dependency of the protocol, 
curcumin was analyzed here as both β-diketo 
and keto-enol tautomers. The results of 10 
independent runs from 10 different starting 
points of each tautomer are presented in table 
VII.  
Based on table VII, the statistical analysis 
of the Tc-PyPLIF values showed that curcumin 
is more likely in the β-diketo tautomer to bind 
to CYP3A4 than in the keto-enol tautomer. 
The Shapiro-Wilk test showed that the data is 
normal (p-value = 0.385). The Tc-PyPLIF 
values of the β-diketo and keto-enol tautomers 
are 0.610 ± 0.036 and 0.569 ± 0.037. The one-
tailed t-test showed that the Tc-PyPLIF values 
of the β-diketo form are higher than the Tc-
PyPLIF values of the keto-enol form 
significantly in the confidence level of 95% (p-
value = 0.012). This indicates that the β-diketo 
form of curcumin is the more plausible 
tautomer than the keto-enol form of curcumin 
when binds to CYP3A4. 
 
The first step metabolism of curcumin 
by CYP3A4 is O-demethylation 
The representative figure depicted how 
curcumin binds to CYP3A4 in the binding 
pocket (Figure 2A) was prepared from the 
result of in silico screening with highest Tc-
PYPLIF value (0.684). Figure 2B shows 
curcumin atoms within 6.0Å from the CYP3A4 
heme Fe-atom which can be defined as the 
SOM of curcumin by CYP3A4 (Rendic, 2002; 
de Graaf et al., 2006). The most frequent 
reaction catalyzed by CYP3A4 is O-
dealkylation (Rendic, 2002). Based on Figure 
2B, there is  a moiety  in curcumin  within 6.0Å  
from the CYP3A4 heme Fe-atom that can be 
metabolized by O-dealkylation reaction, i.e. O-
methoxy moiety. Therefore, the first reaction 
metabolism by CYP3A4 of curcumin is O-
demethylation with an oxidative metabolite 1-
(3,4-dihydroxyphenyl)-5-hydroxy-7-(4-hydroxy-
3-methoxy-phenyl)hepta-1,4,6-trien-3-one 
(Fig.3) as the first plausible metabolite. This 
confirms the newly identified curcumin 
metabolites by Tamvakopoulos et al. (2007). 
Together with the results presented by 
Tamvakopoulos et al. (2007), these in silico 
screening results suggest that curcumin is not 
only a ligand nor an inhibitor to human 
CYP3A4 (Appiah-Opong et al., 2009), but also 
a substrate metabolized by the enzyme to an 
oxidative metabolite 1-(3,4-dihydroxyphenyl)-5-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)hepta-
1,4,6-trien-3-one. In contrary, some in vitro and 
in vivo studies (which mostly employing animal 
models) performed previously stated that no 
oxidative metabolite of curcumin was observed 
(Asai and Miyazawa, 2000; Ireson et al., 2001; 
Hoehle et al., 2006; Anand et al., 2007). These 
recent findings of the trace of oxidative 
metabolites of curcumin (Tamvakopoulos et al., 
2007) and the mechanism of oxidative 
metabolites formation of curcumin in the 
atomic level (presented in this article) open new 
insight of the curcumin metabolism by human 
CYP450, especially by CYP3A4.   
 
CONCLUSIONS 
The validated in silico protocols to 
identify ligands for human CYP3A4 can 
successfully identify the more plausible 
tautomeric form of curcumin when binds to 
human CYP3A4. Employing the best pose of 
curcumin in the binding pocket of human 
CYP3A4 selected by protocols and using the 
criteria proposed by de Graaf et al. (de Graaf et 
al., 2006), the first oxidative product of 
curcumin metabolism by human CYP3A4, 1-
(3,4-dihydroxyphenyl)-5-hydroxy-7-(4-hydroxy-
3-methoxy-phenyl)hepta-1,4,6-trien-3-one, can 
be identified.     
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